Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxResearchers Develop Liquid Biopsy Test for Pediatric Solid Tumors

The first version of the test, launched in November 2022, assesses chromosomal copy number changes in blood, cerebrospinal fluid, and the aqueous humor of the eye to aid in the clinical diagnosis of patients with solid tumors, brain tumors, and retinoblastoma, respectively. The next version of the clinical assay, which will be available in about six months, will detect mutations and gene fusions.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form